METHOD FOR CHOOSING APPROACH FOR NEOADJUVANT DRUG THERAPY FOR LUMINAL T2N0M0 BREAST CANCER Russian patent published in 2025 - IPC G01N33/86 G06M11/02 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and can be used for choosing a neoadjuvant drug therapy approach to luminal T2N0M0 breast cancer. Whole blood is sampled, analysed for blood hypercoagulation and analysed for a relative amount of neutrophil extracellular traps. If no hypercoagulation is detected, while a relative quantity of neutrophil extracellular traps is less than or equal to 1.5%, neoadjuvant drug therapy is not conducted. If hypercoagulation is detected, and a relative amount of neutrophil extracellular traps is more than 1.5%, neoadjuvant chemotherapy is prescribed. If either hypercoagulation, or a relative quantity of neutrophil extracellular traps is more than 1.5%, neoadjuvant hormonotherapy is prescribed.

EFFECT: method provides higher recurrence- and overall survival in the patients with the luminal subtype of breast cancer ensured by examining the blood hypercoagulation and determining a relative number of blood neutrophil extracellular traps.

1 cl, 5 ex